Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
NuvaRing is a novel combined contraceptive vaginal ring that releases 15 microg of ethinylestradiol and 120 microgram etonogestrel per day. Each ring is used for one cycle, comprising 3 weeks continuous use of the ring followed by a 1-week ring-free period. The contraceptive efficacy and safety of NuvaRing have been studied in a 1-year, open study conducted in 1,145 women. Six pregnancies occurred in 12,109 cycles of exposure, giving a Pearl index of 0.65 (95% confidence interval (CI), 0.24-1.41). However, three of the six women violated the NuvaRing regimen in the cycle of conception. Compliance with the prescribed regimen was high, with criteria being fulfilled in 90.8% of cycles. During the 1 year of the study, 41% of the women did not experience any adverse events. The most frequently reported treatment-related adverse events were headache (6.6%), leukorrhea (5.3%) and vaginitis (5.0%). There was a low incidence of estrogen-related adverse events such as nausea (2.8%) and breast tenderness (1.9%). A total of 173 women (15.1%) discontinued due to an adverse event, with device-related events (comprising ring expulsion, foreign body sensation or coital problems) being the most commonly reported (2.6%). There were no clinically relevant changes in blood biochemistry, hematology, blood pressure, heart rate, body weight, physical examination or cervical cytology. In conclusion, NuvaRing is an effective contraceptive that is well tolerated, has a good safety profile and is not associated with unwanted effects on the cervix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition
Mulders, T. M. T., & Dieben, T. O. M. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(01)01689-2 · Cited by 170
Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring
Weisberg, E., Fraser, I. S., Lacarra, M., Mishell, D. R., Alvarez, F., Brache, V, & Nash, H. A. (1999) · Contraception · doi:10.1016/s0010-7824(99)00035-9 · Cited by 43
Cited by
Cardiovascular Physiology of Pregnancy
Sanghavi, M., & Rutherford, J. D. (2014) · Circulation · doi:10.1161/circulationaha.114.009029 · Cited by 1,188
The use of mucoadhesive polymers in vaginal delivery
VALENTA, C. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.07.004 · Cited by 372
The effect of oral contraceptives on the nitric oxide system and renal function
Cherney, D. Z. I., Scholey, J. W., Cattran, D. C., Kang, A. K., Zimpelmann, J., Kennedy, C., Lai, V., Burns, K. D., & Miller, J. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00351.2007 · Cited by 33
Bird, S. T., Delaney, J. A. C., Etminan, M., Brophy, J. M., & Hartzema, A. G. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12224 · Cited by 22
Cagnacci, A., Zanin, R., Napolitano, A., Arangino, S., & Volpe, A. (2013) · Contraception · doi:10.1016/j.contraception.2013.04.003 · Cited by 21
Metadata
- Authors
- Roumen, F.
- Venue
- The European Journal of Contraception & Reproductive Health Care
- Publisher
- Informa UK Limited
- Published
- 2002-12
- Volume
- 7
- Issue
- sup2
- Pages
- 19-24
- ISSN
- 1362-5187 (ISSN-L)
- 1473-0782
- OpenAlex
- W60576798
- Cited by
- 68
- References
- 2
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. https://app.cochat.ai/papers/10.1080/13625187.2002.11949331
- The paper
- Roumen, F. (2002). Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. The European Journal of Contraception & Reproductive Health Care. https://doi.org/10.1080/13625187.2002.11949331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.